{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T14:44:34Z","timestamp":1751467474453},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11899-019-00549-1","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T05:20:32Z","timestamp":1573104032000},"page":"501-506","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?"],"prefix":"10.1007","volume":"14","author":[{"given":"Naranie","family":"Shanmuganathan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Branford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,7]]},"reference":[{"issue":"3","key":"549_CR1","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/ijms20030789","volume":"20","author":"P Valent","year":"2019","unstructured":"Valent P, Kern W, Hoermann G, Milosevic Feenstra JD, Sotlar K, Pfeilst\u00f6cker M, et al. Clonal hematopoiesis with oncogenic potential (CHOP): separation from CHIP and roads to AML. Int J Mol Sci. 2019;20(3):789. \nhttps:\/\/doi.org\/10.3390\/ijms20030789\n\n.","journal-title":"Int J Mol Sci."},{"issue":"2","key":"549_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/35101031","volume":"1","author":"AG Knudson","year":"2001","unstructured":"Knudson AG. Two genetic hits (more or less) to cancer. Nature reviews Cancer. 2001;1(2):157\u201362. \nhttps:\/\/doi.org\/10.1038\/35101031\n\n.","journal-title":"Nature reviews Cancer."},{"issue":"15","key":"549_CR3","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMra020777","volume":"349","author":"JM Goldman","year":"2003","unstructured":"Goldman JM, Melo JV. Chronic myeloid leukemia \u2014 advances in biology and new approaches to treatment. N Engl J Med. 2003;349(15):1451\u201364. \nhttps:\/\/doi.org\/10.1056\/NEJMra020777\n\n.","journal-title":"N Engl J Med"},{"issue":"6","key":"549_CR4","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"Michele Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122. \nhttps:\/\/doi.org\/10.1182\/blood-2013-05-501569\n\n.","journal-title":"Blood"},{"issue":"20","key":"549_CR5","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405. \nhttps:\/\/doi.org\/10.1182\/blood-2016-03-643544\n\n.","journal-title":"Blood."},{"issue":"23","key":"549_CR6","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1516192\n\n.","journal-title":"N Engl J Med."},{"issue":"11","key":"549_CR7","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"Stephen G. O'Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348. \nhttps:\/\/doi.org\/10.1056\/NEJMoa022457\n\n.","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"549_CR8","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260\u201370. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1002315\n\n.","journal-title":"N Engl J Med"},{"issue":"24","key":"549_CR9","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim D-W, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251\u20139. \nhttps:\/\/doi.org\/10.1056\/NEJMoa0912614\n\n.","journal-title":"N Engl J Med"},{"issue":"28","key":"549_CR10","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"Jorge E. Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicius L. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Onc. 2012;30. \nhttps:\/\/doi.org\/10.1200\/jco.2011.38.7522\n\n.","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"549_CR11","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917\u201327. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1609324\n\n.","journal-title":"N Engl J Med."},{"issue":"5","key":"549_CR12","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044\u201354. \nhttps:\/\/doi.org\/10.1038\/leu.2016.5\n\n.","journal-title":"Leukemia."},{"issue":"20","key":"549_CR13","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"Jorge E. Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Onc. 2016. \nhttps:\/\/doi.org\/10.1200\/jco.2015.64.8899\n\n.","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"549_CR14","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/asheducation-2007.1.384","volume":"2007","author":"JP Radich","year":"2007","unstructured":"\u2022 Radich JP. The biology of CML blast crisis. ASH Education Program Book. 2007;2007(1):384\u201391. \nhttps:\/\/doi.org\/10.1182\/asheducation-2007.1.384\n\n. One of the earliest reviews into genes cooperating with BCR-ABL1 in blast crisis CML.","journal-title":"ASH Education Program Book"},{"issue":"11","key":"549_CR15","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/s1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029\u201335. \nhttps:\/\/doi.org\/10.1016\/s1470-2045(10)70233-3\n\n.","journal-title":"Lancet Oncol."},{"issue":"4","key":"549_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515\u201322. \nhttps:\/\/doi.org\/10.1182\/blood-2013-02-483750\n\n.","journal-title":"Blood."},{"issue":"6","key":"549_CR17","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747\u201357. \nhttps:\/\/doi.org\/10.1016\/S1470-2045(18)30192-X\n\n.","journal-title":"Lancet Oncol."},{"issue":"4944","key":"549_CR18","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"G Daley","year":"1990","unstructured":"Daley G, Van Etten R, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science (New York, NY). 1990;247(4944):824\u201330. \nhttps:\/\/doi.org\/10.1126\/science.2406902\n\n.","journal-title":"Science (New York, NY)"},{"issue":"10","key":"549_CR19","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/blood.V92.10.3829","volume":"92","author":"X Zhang","year":"1998","unstructured":"Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood. 1998;92(10):3829\u201340.","journal-title":"Blood."},{"issue":"1","key":"549_CR20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1182\/blood.V58.1.158.158","volume":"58","author":"PJ Fialkow","year":"1981","unstructured":"Fialkow PJ, Martin PJ, Najfeld V, Penfold GK, Jacobson RJ, Hansen JA. Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood. 1981;58(1):158\u201363.","journal-title":"Blood."},{"issue":"4","key":"549_CR21","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3892\/mmr.2014.1951","volume":"9","author":"SI Ismail","year":"2014","unstructured":"Ismail SI, Naffa RG, Yousef AM, Ghanim MT. Incidence of bcr-abl fusion transcripts in healthy individuals. Mol Med Reports. 2014;9(4):1271\u20136. \nhttps:\/\/doi.org\/10.3892\/mmr.2014.1951\n\n.","journal-title":"Mol Med Reports."},{"issue":"4","key":"549_CR22","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.4238\/2013.October.24.8","volume":"12","author":"JA Boquett","year":"2013","unstructured":"Boquett JA, Alves JR, de Oliveira CE. Analysis of BCR\/ABL transcripts in healthy individuals. Genet Mol Res. 2013;12(4):4967\u201371. \nhttps:\/\/doi.org\/10.4238\/2013.October.24.8\n\n.","journal-title":"Genet Mol Res."},{"issue":"2","key":"549_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s00277-002-0427-x","volume":"81","author":"J Basecke","year":"2002","unstructured":"Basecke J, Griesinger F, Trumper L, Brittinger G. Leukemia- and lymphoma-associated genetic aberrations in healthy individuals. Ann Hematol. 2002;81(2):64\u201375. \nhttps:\/\/doi.org\/10.1007\/s00277-002-0427-x\n\n.","journal-title":"Ann Hematol."},{"key":"549_CR24","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann R, Lauseker M, Sau\u00dfele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398\u2013406. \nhttps:\/\/doi.org\/10.1038\/leu.2017.253\n\n.","journal-title":"Leukemia."},{"issue":"4","key":"549_CR25","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1182\/blood-2003-01-0123","volume":"102","author":"BJ Huntly","year":"2003","unstructured":"Huntly BJ, Bench A, Green AR. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood. 2003;102(4):1160\u20138. \nhttps:\/\/doi.org\/10.1182\/blood-2003-01-0123\n\n.","journal-title":"Blood."},{"issue":"8","key":"549_CR26","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Cortes J. Molecular biology of bcr-abl1\u2013positive chronic myeloid leukemia. Blood. 2009;113(8):1619\u201330. \nhttps:\/\/doi.org\/10.1182\/blood-2008-03-144790\n\n.","journal-title":"Blood."},{"issue":"1","key":"549_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","volume":"129","author":"T Kim","year":"2017","unstructured":"\u2022\u2022 Kim T, Tyndel MS, Kim HJ, Ahn JS, Choi SH, Park HJ, et al. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood. 2017;129(1):38\u201347. \nhttps:\/\/doi.org\/10.1182\/blood-2016-04-708560\n\n. Exploration of the genomic landscape of CML.","journal-title":"Blood"},{"issue":"1","key":"549_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","volume":"38","author":"S Soverini","year":"2014","unstructured":"\u2022 Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res. 2014;38(1):10\u201320. \nhttps:\/\/doi.org\/10.1016\/j.leukres.2013.09.011\n\n. Investigation into the implication of kinase domain mutations in CML.","journal-title":"Leuk Res"},{"issue":"10","key":"549_CR29","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1182\/blood-2011-08-375535","volume":"119","author":"WT Parker","year":"2012","unstructured":"Parker WT, Ho M, Scott HS, Hughes TP, Branford S. Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. Blood. 2012;119(10):2234\u20138. \nhttps:\/\/doi.org\/10.1182\/blood-2011-08-375535\n\n.","journal-title":"Blood."},{"issue":"5","key":"549_CR30","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"Simona Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011. \nhttps:\/\/doi.org\/10.1182\/blood-2010-12-326405\n\n.","journal-title":"Blood"},{"issue":"32","key":"549_CR31","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1200\/jco.2011.35.0934","volume":"29","author":"WT Parker","year":"2011","unstructured":"Parker WT, Lawrence RM, Ho M, Irwin DL, Scott HS, Hughes TP, et al. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. J Clin Onc. 2011;29(32):4250\u20139. \nhttps:\/\/doi.org\/10.1200\/jco.2011.35.0934\n\n.","journal-title":"J Clin Onc."},{"issue":"26","key":"549_CR32","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","volume":"118","author":"A Fabarius","year":"2011","unstructured":"\u2022 Fabarius A, Leitner A, Hochhaus A, M\u00fcller MC, Hanfstein B, Haferlach C, et al. Impact of ACA at diagnosis on prognosis of CML: long-term observation from 1151 patients of the randomized CML Study IV. Blood. 2011;118(26):6760\u20138. \nhttps:\/\/doi.org\/10.1182\/blood-2011-08-373902\n\n. Impact of additional cytogenetic abnormalities on outcomes in CML.","journal-title":"Blood"},{"issue":"4","key":"549_CR33","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","volume":"120","author":"S Luatti","year":"2012","unstructured":"\u2022 Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I, et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood. 2012;120(4):761\u20137. \nhttps:\/\/doi.org\/10.1182\/blood-2011-10-384651\n\n. Impact of additional cytogenetic abnormalities on outcomes in CML.","journal-title":"Blood"},{"issue":"1","key":"549_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/ajh.24943","volume":"93","author":"A Alhuraiji","year":"2018","unstructured":"\u2022 Alhuraiji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, Di Nardo C, et al. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol. 2018;93(1):84\u201390. \nhttps:\/\/doi.org\/10.1002\/ajh.24943\n\n. Impact of additional cytogenetic abnormalities on outcomes in CML.","journal-title":"Am J Hematol"},{"issue":"24","key":"549_CR35","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1158\/1078-0432.ccr-09-1068","volume":"15","author":"D Milojkovic","year":"2009","unstructured":"Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Canc Research. 2009;15(24):7519\u201327. \nhttps:\/\/doi.org\/10.1158\/1078-0432.ccr-09-1068\n\n.","journal-title":"Clin Canc Research."},{"issue":"3","key":"549_CR36","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/clpt.2013.208","volume":"95","author":"LN Eadie","year":"2014","unstructured":"Eadie LN, Hughes TP, White DL. Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. Clinical Pharmacology & Therapeutics. 2014;95(3):294\u2013306. \nhttps:\/\/doi.org\/10.1038\/clpt.2013.208\n\n.","journal-title":"Clinical Pharmacology & Therapeutics."},{"issue":"16","key":"549_CR37","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1200\/jco.2009.26.5819","volume":"28","author":"DL White","year":"2010","unstructured":"White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Onc. 2010;28(16):2761\u20137. \nhttps:\/\/doi.org\/10.1200\/jco.2009.26.5819\n\n.","journal-title":"J Clin Onc."},{"issue":"11","key":"549_CR38","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","volume":"103","author":"B Calabretta","year":"2004","unstructured":"Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103(11):4010\u201322. \nhttps:\/\/doi.org\/10.1182\/blood-2003-12-4111\n\n.","journal-title":"Blood."},{"issue":"9","key":"549_CR39","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","volume":"132","author":"S Branford","year":"2018","unstructured":"\u2022\u2022 Branford S, Wang P, Yeung DT, Thomson D, Purins A, Wadham C, et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood. 2018;132(9):948\u201361. \nhttps:\/\/doi.org\/10.1182\/blood-2018-02-832253\n\n. Exploration of the genomic landscape of CML.","journal-title":"Blood"},{"issue":"1","key":"549_CR40","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/asheducation-2005.1.188","volume":"2005","author":"RL Ilaria","year":"2005","unstructured":"\u2022 Ilaria RL. Pathobiology of lymphoid and myeloid blast crisis and management issues. ASH Education Program Book. 2005;2005(1):188\u201394. \nhttps:\/\/doi.org\/10.1182\/asheducation-2005.1.188\n\n. Exploration of blast crisis pathogenesis.","journal-title":"ASH Education Program Book"},{"issue":"24","key":"549_CR41","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1158\/1078-0432.ccr-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"\u2022 Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12(24):7374\u20139. \nhttps:\/\/doi.org\/10.1158\/1078-0432.ccr-06-1516\n\n. Impact of kinase domain mutations in CML.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"549_CR42","doi-asserted-by":"publisher","first-page":"6293","DOI":"10.1073\/pnas.88.14.6293","volume":"88","author":"E Feinstein","year":"1991","unstructured":"Feinstein E, Cimino G, Gale RP, Alimena G, Berthier R, Kishi K, et al. p53 in chronic myelogenous leukemia in acute phase. Proceedings of the National Academy of Sciences of the United States of America. 1991;88(14):6293\u20137. \nhttps:\/\/doi.org\/10.1073\/pnas.88.14.6293\n\n.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America."},{"issue":"17","key":"549_CR43","doi-asserted-by":"publisher","first-page":"6783","DOI":"10.1073\/pnas.86.17.6783","volume":"86","author":"H Ahuja","year":"1989","unstructured":"Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 1989;86(17):6783\u20137. \nhttps:\/\/doi.org\/10.1073\/pnas.86.17.6783\n\n.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America."},{"issue":"6","key":"549_CR44","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1172\/JCI115234","volume":"87","author":"H Ahuja","year":"1991","unstructured":"Ahuja H, Bar-Eli M, Arlin Z, Advani S, Allen SL, Goldman J, et al. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest. 1991;87(6):2042\u20137. \nhttps:\/\/doi.org\/10.1172\/JCI115234\n\n.","journal-title":"J Clin Invest."},{"key":"549_CR45","doi-asserted-by":"crossref","unstructured":"Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 2019; (accepted for publication).","DOI":"10.1038\/s41375-019-0512-y"},{"issue":"5","key":"549_CR46","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/leu.2011.7","volume":"25","author":"LF Peterson","year":"2011","unstructured":"Peterson LF, Mitrikeska E, Giannola D, Lui Y, Sun H, Bixby D, et al. p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells. Leukemia. 2011;25(5):761\u20139. \nhttps:\/\/doi.org\/10.1038\/leu.2011.7\n\n.","journal-title":"Leukemia."},{"issue":"3","key":"549_CR47","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1365-2141.1995.tb05358.x","volume":"91","author":"A Serra","year":"1995","unstructured":"Serra A, Gottardi E, Della Ragione F, Saglio G, Iolascon A. Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia. Br J Haematol. 1995;91(3):625\u20139.","journal-title":"Br J Haematol."},{"issue":"3","key":"549_CR48","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/leu.2010.298","volume":"25","author":"V Grossmann","year":"2011","unstructured":"Grossmann V, Kohlmann A, Zenger M, Schindela S, Eder C, Weissmann S, et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia. 2011;25(3):557\u201360. \nhttp:\/\/www.nature.com\/leu\/journal\/v25\/n3\/suppinfo\/leu2010298s1.html\n\n.","journal-title":"Leukemia"},{"key":"549_CR49","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc2368","volume":"8","author":"M Savona","year":"2008","unstructured":"Savona M, Talpaz M. Getting to the stem of chronic myeloid leukaemia. Nature Reviews Cancer. 2008;8:341\u201350. \nhttps:\/\/doi.org\/10.1038\/nrc2368\n\n.","journal-title":"Nature Reviews Cancer."},{"key":"549_CR50","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrc2368-c1","volume":"8","author":"RT Williams","year":"2008","unstructured":"Williams RT, Sherr CJ. BCR\u2013ABL and CDKN2A: a dropped connection. Nature Reviews Cancer. 2008;8:563. \nhttps:\/\/doi.org\/10.1038\/nrc2368-c1\n\n.","journal-title":"Nature Reviews Cancer."},{"issue":"4","key":"549_CR51","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3324\/haematol.2017.185603","volume":"103","author":"R Marke","year":"2018","unstructured":"Marke R, van Leeuwen FN, Scheijen B. The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2018;103(4):565\u201374. \nhttps:\/\/doi.org\/10.3324\/haematol.2017.185603\n\n.","journal-title":"Haematologica."},{"issue":"7","key":"549_CR52","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1172\/JCI41246","volume":"120","author":"D Perrotti","year":"2010","unstructured":"Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120(7):2254\u201364. \nhttps:\/\/doi.org\/10.1172\/JCI41246\n\n.","journal-title":"J Clin Invest."},{"key":"549_CR53","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/leu.2010.69","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24:1128\u201338. \nhttps:\/\/doi.org\/10.1038\/leu.2010.69\n\n.","journal-title":"Leukemia."},{"issue":"20","key":"549_CR54","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1182\/blood-2010-05-283291","volume":"116","author":"WC Chou","year":"2010","unstructured":"Chou WC, Huang HH, Hou HA, Chen CY, Tang JL, Yao M, et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood. 2010;116(20):4086\u201394. \nhttps:\/\/doi.org\/10.1182\/blood-2010-05-283291\n\n.","journal-title":"Blood."},{"issue":"4","key":"549_CR55","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347. \nhttps:\/\/doi.org\/10.1182\/blood-2016-08-733196\n\n.","journal-title":"Blood."},{"issue":"10","key":"549_CR56","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/leu.2011.139","volume":"25","author":"C Roche-Lestienne","year":"2011","unstructured":"Roche-Lestienne C, Marceau A, Labis E, Nibourel O, Coiteux V, Guilhot J, et al. Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia. Leukemia. 2011;25(10):1661\u20134. \nhttps:\/\/doi.org\/10.1038\/leu.2011.139\n\n.","journal-title":"Leukemia."},{"issue":"15","key":"549_CR57","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1182\/blood-2016-09-687822","volume":"129","author":"R Avellino","year":"2017","unstructured":"Avellino R, Delwel R. Expression and regulation of C\/EBP\u03b1 in normal myelopoiesis and in malignant transformation. Blood. 2017;129(15):2083\u201391. \nhttps:\/\/doi.org\/10.1182\/blood-2016-09-687822\n\n.","journal-title":"Blood."},{"issue":"6","key":"549_CR58","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.immuni.2004.11.006","volume":"21","author":"P Zhang","year":"2004","unstructured":"Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, Owens BM, et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C\/EBP alpha. Immunity. 2004;21(6):853\u201363. \nhttps:\/\/doi.org\/10.1016\/j.immuni.2004.11.006\n\n.","journal-title":"Immunity."},{"issue":"8","key":"549_CR59","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/jjco\/hyv064","volume":"45","author":"S Kagita","year":"2015","unstructured":"Kagita S, Uppalapati S, Gundeti S, Digumarti R. Correlation of C\/EBP\u03b1 expression with response and resistance to imatinib in chronic myeloid leukaemia. Jpn J Clin Oncol. 2015;45(8):749\u201354. \nhttps:\/\/doi.org\/10.1093\/jjco\/hyv064\n\n.","journal-title":"Jpn J Clin Oncol."},{"issue":"52","key":"549_CR60","doi-asserted-by":"publisher","first-page":"52651","DOI":"10.1074\/jbc.M307077200","volume":"278","author":"S Tavor","year":"2003","unstructured":"Tavor S, Park DJ, Gery S, Vuong PT, Gombart AF, Koeffler HP. Restoration of C\/EBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation. The Journal of biological chemistry. 2003;278(52):52651\u20139. \nhttps:\/\/doi.org\/10.1074\/jbc.M307077200\n\n.","journal-title":"The Journal of biological chemistry."},{"issue":"3","key":"549_CR61","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cancergencyto.2010.09.001","volume":"204","author":"V Najfeld","year":"2011","unstructured":"Najfeld V, Wisch N, Mascarenhas J, Issa L, Tripodi J, Sidhu M, et al. Development of t(8;21) and RUNX1-RUNX1T1 in the Philadelphia-positive clone of a patient with chronic myelogenous leukemia: additional evidence for multiple steps involved in disease progression. Cancer Genetics. 2011;204(3):165\u201370. \nhttps:\/\/doi.org\/10.1016\/j.cancergencyto.2010.09.001\n\n.","journal-title":"Cancer Genetics."},{"issue":"23","key":"549_CR62","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1182\/blood.V126.23.3737.3737","volume":"126","author":"ST Ong","year":"2015","unstructured":"Ong ST, Pathiraja T, Javed A, Soh XXS, Malik S, Tan JHJ, et al. The genomic and epigenomic landscapes of blast crisis transformation in chronic myeloid leukemia. Blood. 2015;126(23):3737.","journal-title":"Blood"},{"issue":"21","key":"549_CR63","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","volume":"117","author":"H Makishima","year":"2011","unstructured":"Makishima H, Jankowska AM, McDevitt MA, O'Keefe C, Dujardin S, Cazzolli H, et al. CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117(21):e198\u2013206. \nhttps:\/\/doi.org\/10.1182\/blood-2010-06-292433\n\n.","journal-title":"Blood."},{"issue":"12","key":"549_CR64","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275\u201391. \nhttps:\/\/doi.org\/10.1182\/blood-2017-09-801498\n\n.","journal-title":"Blood."},{"issue":"12","key":"549_CR65","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1038\/leu.2014.272","volume":"28","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Rinke J, Schafer V, Schnittger S, Kohlmann A, Obstfelder E, et al. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia. 2014;28(12):2292\u20139. \nhttps:\/\/doi.org\/10.1038\/leu.2014.272\n\n.","journal-title":"Leukemia."}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-019-00549-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-019-00549-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-019-00549-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:30:29Z","timestamp":1604622629000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-019-00549-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,7]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["549"],"URL":"https:\/\/doi.org\/10.1007\/s11899-019-00549-1","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,7]]},"assertion":[{"value":"7 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"N.S. received honoraria from Novartis and Bristol-Myers Squibb and travel and accommodation expenses from Novartis, Gilead, Amgen and Janssen. S.B. is a member of the advisory boards of Qiagen, Novartis and Bristol-Myers Squibb and received honoraria from Qiagen, Novartis, Bristol-Myers Squibb and Cepheid.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}